Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Metarapone

Phase 3Small molecule

IIRCCS Azienda Ospedaliero-Universitaria di Bologna

Metarapone is one of 2 small molecule programs targeting Cardiovascular Risk Factor. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular Risk FactorRecruiting

Cardiovascular Risk FactorPhase 3

Recruiting

Competition

Competitive Landscape

1 competitor in Cardiovascular Risk Factor

#DrugCompanyPhaseTrials

Metarapone

IIRCCS Azienda Ospedaliero-Universitaria di Bologna

Plasma Osteoprotegerin Level

UUniversity Hospital, Montpellier

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiovascular Risk Factor1 trial

Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome

Recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 4·NCT06801249·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Metarapone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metarapone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metarapone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IRCCS Azienda Ospedaliero-Universitaria di Bologna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIRCCS Azienda Ospedaliero-Universitaria di Bologna

Related News